Handbook_Volume III

47 Bibliografia [1] Hurley CK, Oudshoorn M, Setterholm M. Donor registries and search strategies. Methods Mol Biol. 2012;882:531-547. [2] Fernández-Vi a MA, Klein JP, Haagenson M et al Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation, Blood 2013;121:4603–4610. [3] Pidala J, Lee SJ, Ahn KW, et al. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood. 2014;124:25962606. [4] Arora M, Weisdorf DJ, Spellman SR, et al. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol. 2009;27:1644-1652. [5] Furst D, Muller C, Vucinic V, et al. High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis. Blood. 2013;122:3220-3229. [6] Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007;110 (13):4576-4583. [7] Fleischhauer K, Shaw BE, Gooley T, et al. Effect of T-cell-epitope matching at HLADPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol. 2012;13: 366-374 [8] Crivello P, Zito L, Sizzano F, et al. The impact of amino acid variability on alloreactivity defines a functional distance predictive of permissive HLA-DPB1 mismatches in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21(2): 233241. [9] Spencer Mangum D, Caywood E. A clinician’s guide to HLA matching in allogeneic hematopoietic stem cell transplant. Human Immunology. 2022 [10] Picardi A, Sacchi N, Miotti V et al.Allelic HLA matching and pair’s origin represent favourable prognostic factors for Unrelated Haematopoietic Stem Cell Transplantation in neoplastic haematological diseases: an Italian analysis on behalf of GITMO, IBMDR and AIBT Transplantation and Cell Therapy 2021; 406e1-11 [11] Petersdorf EW, Carrington M, O’hUigin C et al. Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. Lancet Haematol 2020; 7: e50–60 [12] Tiercy JM. HLA-C incompatibilities in allogeneic unrelated hematopoietic stem cell transplantation. Frontiers in Immunology 2014, 5:1-5. [13] Fernandez-Vina MA, Wang T, Lee JS et al. Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation. Blood 2014; 123:1270-78 [14] M Eapen, JP Klein, A Ruggeri Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy Blood 2014; 123:133-40 [15] Dehn J, Spellman S, Hurley C.K., et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR, Blood 134 (12) (2019) 924–934 [16] Bashey A, Zhang X, Sizemore CA, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using posttransplantation cyclophosphamide results in outcomes equivalent of contemporaneous HLA-matched related or unrelated donor transplantation. J Clin Oncol. 2013;31:1310–1316 [17] Piemontese S, Ciceri F, Labopin M, et al. A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia. J Hematol Oncol. 2017 Jan 19;10(1):24. [18] Dholaria B, Labopin M, Sanz J, et al. Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia. J Hematol Oncol. 2021 May 3;14(1):76 [19]Kollman C, Spellman SR, Zhang MJ et al. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy, Blood 127 (2) (2016) 260–267. [20] Kollman C, Howe CW, Anasetti C et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98: 2043–2051, [21] F Ayuk, T Zabelina, F Wortmann et al Histocompatibility and Donor Selection Donor choice according to age for allo-SCT for AML in complete remission Bone Marrow Transplantation 2013; 48:1028–1032 (2013) [22] Picardi A, Arcese W, Pollichieni S et al. The Rome Transplant Network model compared to the Italian Bone Marrow Donor Registry activity for unrelated donor search process and transplant efficiency for hematological malignancy Transfusion 2017; 57:1734-1743 [23] Gragert L, Eapen M, Williams E et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. New England Journal of Med 2014; 24; 371:339-48 1. Aspetti Generali